Floatz logo

(R)-2-(5-CYANO-2-(6-(METHOXYCARBONYL)-7-METHYL-3-OXO-8-(3-(TRIFLUOROMETHYL)PHENYL)-2,3,5,8-TETRAHYDRO-(1,2,4)TRIAZOLO(4,3-A)PYRIMIDIN-5-YL)PHENYL)-N,N,N-TRIMETHYLETHANAMINIUM ION

Cystic Fibrosis

Chiesi Farmaceutici S.p.A.Small moleculePhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
73/ 100

Competitive context

82 Active assets in the Cystic Fibrosis cohort.

Asset / SponsorPhaseRating
Tezacaftor
Vertex Pharmaceuticals Incorporated
Phase 4A
Lumacaftor
Hospices Civils de Lyon
Phase 4BBB
Liprotamase
Anthera Pharmaceuticals
Phase 4BBB
Ivacaftor
Meyer Children's Hospital IRCCS
Phase 4BBB
ELEXACAFTOR
Meyer Children's Hospital IRCCS
Phase 4BBB

View all 50 →

Same molecule, other indications

(R)-2-(5-CYANO-2-(6-(METHOXYCARBONYL)-7-METHYL-3-OXO-8-(3-(TRIFLUOROMETHYL)PHENYL)-2,3,5,8-TETRAHYDRO-(1,2,4)TRIAZOLO(4,3-A)PYRIMIDIN-5-YL)PHENYL)-N,N,N-TRIMETHYLETHANAMINIUM ION is also rated in:

bronchiectasisDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →